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INTRODUCTION 82
Ovarian carcinoma (OC) is the most lethal gynaecological malignancy, accounting for over 180,000 83 deaths per year worldwide [1] . OC is now recognised to comprise five core histological subtypes: 84 high grade serous (HGS), endometrioid, clear cell, low grade serous (LGS) and mucinous OC -each 85 displaying distinct molecular landscapes and clinical behaviour [2] . Within HGS cases, homologous 86 recombination deficiency by virtue of BRCA1 or BRCA2 mutation has been associated with favorable 87 outcome, greater sensitivity to platinum-based chemotherapy and marked benefit from poly (ADP-88 ribose) polymerase (PARP) inhibitors [3] [4] [5] [6] . Conversely, CCNE1 copy number gain has been 89 associated with chemoresistance and poorer survival in this group [3, 7] . 90
While most OC cases -particularly HGS OCs -are typically sensitive to chemotherapy in the first-line 91 setting, the majority of patients will experience disease relapse which acquires resistance to 92 chemotherapy [8, 9] . The most common sites of recurrence are the pelvis and peritoneum [10] . 93
Involvement of lymph nodes (LNs) at relapse is common; however, recurrence confined solely to LNs 94 is a rare event, accounting for ≤5% of relapsed OCs [11, 12] . These isolated LN relapse (ILNR) cases 95 have been described as a unique clinical disease entity and are thought to experience a relatively 96 indolent disease course, with a reported median post-relapse survival (PRS) and overall survival (OS) 97 of around 2.5-4 and >5 years, respectively [11] [12] [13] [14] [15] [16] [17] [18] . 98 A number of previous studies have reported on the clinical outcome of apparent ILNR OC 99 (summarised in Table 1) [11] [12] [13] [14] [15] [16] [17] [18] . Many of these studies have reported only a small number of cases 100 [11, 13, 17, 18] , with a minority reporting larger numbers identified from multiple centres [14, 16] . 101
To our knowledge, none of these studies have compared outcome directly to a matched extra-nodal 102 M A N U S C R I P T 
A C C E P T E D ACCEPTED MANUSCRIPT
Assessment of tumor infiltrating lymphocyte density 161
Tumor infiltrating lymphocytes (TILs) were assessed using 4µm FFPE sections of diagnostic tumor 162 material from first-line cytoreductive surgery. IHC for CD3 and CD8 was performed using Bond 163 ready-to-use CD8-4B11 and CD3-LN10 antibodies (Leica Biosystems) on the Leica Bond III 164
Autostainer. Human tonsil was used as a positive control for both markers. Stained slides were 165 digitized and marker-positive cells were quantified using QuPath [20] 
Statistical analyses 176
Statistical analyses were performed using R version 3.5.1. Disease-free interval (DFI) was calculated 177 as time from end of first-line chemotherapy to disease recurrence. Comparisons of OS and PRS were 178 conducted using Cox proportional hazards regression models within the Survival R package [21] and 179 presented as hazard ratios (HRs) alongside their 95% confidence intervals (CIs). Frequency 180 comparisons were made using the Chi-squared test and Fisher's exact test as appropriate. 181
Comparisons of TIL density were made using the Mann Whitney-U test. Analyses were adjusted for 182 multiplicity of testing using the Bonferroni correction, where specified. 183
184
RESULTS
185
Cohort Characteristics 186
Demographics of the ILNR and ENR cohorts are summarised in Table 2 . There was no significant 187 difference in age at diagnosis, RD following primary surgical debulking, histology or grade of disease 188 at diagnosis, or disease stage at diagnosis between the ILNR and ENR groups. These data indicate 189 good fidelity of the ILNR-ENR matching process. Patterns of ILNR are described in Table 3 . 
Principle findings 236
The principle findings of this study are: (i) ILNR represents a distinct pattern of OC relapse with 237 prolonged survival versus ENR cases; (ii) longer DFI prior to ILNR is associated with prolonged PRS in 238 ILNR; (iii) ILNR OC do not demonstrate significantly differential composition of known genomic 239 subtypes associated with prognosis, namely BRCA1/2 mutation or gain of CCNE1; (iv) cases that go 240
on to experience ILNR demonstrate greater TIL burden at diagnosis compared to ENR cases. 241
Study strengths and limitations 242
A key strength of this study is the direct comparison of ILNR OC to matched ENR cases: a number of 243 studies have reported ILNR as a distinct pattern of OC relapse with a relatively indolent disease 244 course, but have not systematically compared ILNR cases directly to a matched ENR cohort [11] [12] [13] [14] [15] [16] [17] [18] . 245 M A N U S C R I P T While this study does represent one of the largest reported ILNR OC cohorts, case numbers were still 256 restricted due to the rarity of ILNR OC. In particular, power to detect differential outcome between 257 distinct patterns of ILNR was limited, and we could not perform meaningful analysis comparing rates 258 of rare genomic events present in both ILNR and ENR cohort, including mutational events in RB1, 259 NF1 and PTEN, as well as gene-specific analysis of BRCA1 and BRCA2. Other limitations of this study 260 include heterogeneous treatment of OC patients across the time period in which these cases were 261 diagnosed, though diagnosis periods were comparable between the ILNR and ENR cohorts (Table 2) . 262
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Clinical outcome in ILNR OC 263
The median PRS and OS of ILNR cases was approximately 2.7 and 6 years, consistent with previous 264 reports of ILNR OC [11] [12] [13] [14] [15] [16] [17] [18] . ILNR cases displayed significantly prolonged OS and PRS compared to 265 their ENR counterparts upon multivariable analysis (HR multi =0.51 and 0.52 for OS and PRS). Critically, 266 this difference was maintained in a histotype-specific analysis of HGS cases, which account for the 267 majority of OCs. To our knowledge, this is the first report directly demonstrating a significant 268 difference in outcome between ILNR and ENR OC. 269 Notably, the intervals considered in our study are akin to those used clinically to define platinum 277 sensitivity in unselected relapsed OC [23] . Supplementary table legends  416   Table S1 . Tolerances for electronic matching of ENR to ILNR 417 Table S2 . Cellularity of specimens used for DNA extraction 418 Table S3 . Frequency of patients with detrimental mutations in genes sequenced on IDT gene capture 419 NGS panel 420 Table S4 . Multivariable analysis for OS in ILNR vs ENR in OC 421 Table S5 . Multivariable analysis of time to ILNR as a predictor of PRS in ILNR OC 422 Table S6 . Univariable analyses of specific LN site involvement and association with PRS 423 M A N U S C R I P T
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ii coding variants and missense variants of undocumented significance were discarded as variants of 26 uncertain significance. 27 TP53 mutations were classified independently with additional reference to the UMD TP53 variation 28 database (9). Manual review of aligned sequence read for the supposed TP53 wild-type OCs (6 HGS, 29 4 endometrioid, 3 LGS, 1 mixed serous/endometrioid) was performed owing to the known high TP53 30 mutation rate in OC (particularly in HGS OCs). These analyses revealed further high confidence 31 pathogenic mutations affecting splice sites in 4 HGS OC cases, two of which were present in the 32 callset from a single caller and hence didn't qualify for the ensemble callset. The apparent poorer 33 sensitivity to splice site events was attributed to the proximity of these variants to read ends, 34 compounded by the relatively reduced coverage at exon-intron boundaries owing to the capture 35 design being targeted toward coding regions. 
